July 23, 2026

FDA Approves Zidesamtinib for Second-Line Treatment of ROS1-Positive NSCLC

The ROS1 selective inhibitor was approved for the treatment of adult patients with locally advanced or metastatic ROS1-positive non–small cell lung cancer (NSCLC) who received a prior ROS1 kinase inhi...

The ASCO Post

July 23, 2026

FDA Approves Zidesamtinib for Second-Line Treatment of ROS1-Positive NSCLC

The ROS1 selective inhibitor was approved for the treatment of adult patients with locally advanced or metastatic ROS1-positive non–small cell lung cancer (NSCLC) who received a prior ROS1 kinase inhi...

The ASCO Post

July 15, 2026

Over 50 Million Americans Live in Counties Without a Radiation Oncology Clinic

The national analysis found that from 2018 to 2025, radiation oncology practice sites disproportionately disappeared from rural areas and freestanding, community-based settings, raising concerns about...

The ASCO Post

July 15, 2026

Over 50 Million Americans Live in Counties Without a Radiation Oncology Clinic

The national analysis found that from 2018 to 2025, radiation oncology practice sites disproportionately disappeared from rural areas and freestanding, community-based settings, raising concerns about...

The ASCO Post

July 14, 2026

Adjuvant Selpercatinib Deemed ‘Immediately Practice-Changing’ in Early-Stage RET Fusion–Positive NSCLC

The phase III LIBRETTO-432 trial of adjuvant therapy with the central nervous system (CNS)–penetrant oral RET inhibitor selpercatinib met its primary endpoint of improved event-free survival in patien...

The ASCO Post

July 14, 2026

Aumolertinib Plus Chemotherapy in EGFR-Mutated Advanced NSCLC

In a Chinese phase III trial (AENEAS2) reported in The Lancet Oncology, Li et al found that the combination of aumolertinib with chemotherapy significantly improved progression-free survival vs aumole...

The ASCO Post

July 06, 2026

ACP Ranks Obesity Drug Options

A living clinical guideline outlines a treatment hierarchy for selected pharmacologic therapies in patients with obesity and selected patients with overweight.

MDSpire News

July 06, 2026

Early Myocarditis After Immune Checkpoint Inhibitors Signals Elevated Mortality Risk

Early onset of immune checkpoint inhibitor (ICI)–related myocarditis is associated with increased mortality risk, as is the presence of concurrent major adverse cardiac events, according to results pr...

The ASCO Post

July 06, 2026

Early Myocarditis After Immune Checkpoint Inhibitors Signals Elevated Mortality Risk

Early onset of immune checkpoint inhibitor (ICI)–related myocarditis is associated with increased mortality risk, as is the presence of concurrent major adverse cardiac events, according to results pr...

The ASCO Post

June 25, 2026

Update to ASCO Guideline on Advanced NSCLC Without Driver Alterations Adds Retifanlimab to Treatment Options

ASCO has issued an update to its living guideline on systemic therapies for patients with stage IV NSCLC without driver alterations.1 The update, which includes a new recommendation regarding the PD-1...

The ASCO Post